PT1937262T - Composição para utilização no tratamento de dismotilidade gastrointestinal - Google Patents

Composição para utilização no tratamento de dismotilidade gastrointestinal

Info

Publication number
PT1937262T
PT1937262T PT06825239T PT06825239T PT1937262T PT 1937262 T PT1937262 T PT 1937262T PT 06825239 T PT06825239 T PT 06825239T PT 06825239 T PT06825239 T PT 06825239T PT 1937262 T PT1937262 T PT 1937262T
Authority
PT
Portugal
Prior art keywords
composition
treating gastrointestinal
gastrointestinal dysmotility
dysmotility
treating
Prior art date
Application number
PT06825239T
Other languages
English (en)
Inventor
Xin Dong Zheng
Datta Rakesh
Original Assignee
Ipsen Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ipsen Pharma Sas filed Critical Ipsen Pharma Sas
Publication of PT1937262T publication Critical patent/PT1937262T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
PT06825239T 2005-09-29 2006-09-28 Composição para utilização no tratamento de dismotilidade gastrointestinal PT1937262T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72191605P 2005-09-29 2005-09-29

Publications (1)

Publication Number Publication Date
PT1937262T true PT1937262T (pt) 2019-08-21

Family

ID=37906731

Family Applications (1)

Application Number Title Priority Date Filing Date
PT06825239T PT1937262T (pt) 2005-09-29 2006-09-28 Composição para utilização no tratamento de dismotilidade gastrointestinal

Country Status (14)

Country Link
US (6) US7932231B2 (pt)
EP (2) EP3586846A1 (pt)
JP (4) JP5230430B2 (pt)
CN (3) CN105381453B9 (pt)
CA (1) CA2625447C (pt)
CY (1) CY1122134T1 (pt)
DK (1) DK1937262T3 (pt)
ES (1) ES2740108T3 (pt)
HU (1) HUE044391T2 (pt)
PL (1) PL1937262T3 (pt)
PT (1) PT1937262T (pt)
RU (2) RU2566708C2 (pt)
SI (1) SI1937262T1 (pt)
WO (1) WO2007041278A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI331922B (en) * 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
CN101282738B (zh) * 2005-09-28 2015-09-16 益普生制药股份有限公司 生长素释放肽类似物
PL1937262T3 (pl) * 2005-09-29 2019-10-31 Ipsen Pharma Kompozycja do stosowania w leczeniu zaburzeń motoryki przewodu pokarmowego
EP2644618B1 (en) 2007-02-09 2016-08-17 Ocera Therapeutics, Inc. tether intermediates for the synthesis of macrocyclic ghrelin receptor modulators
AU2013201451B2 (en) * 2007-08-08 2015-07-30 Ipsen Pharma S.A.S. Method for inhibiting inflammation and pre-inflammatory cytokine/chemokine expression using a ghrelin analogue
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
EP2234630A4 (en) * 2007-12-21 2012-08-08 Helsinn Therapeutics Us Inc METHOD OF STIMULATING THE MOTILITY OF THE GASTROINTESTINAL SYSTEM USING IPAMORELIN
US8772229B2 (en) 2008-10-03 2014-07-08 The Johns Hopkins University Methods for synthesis and uses of inhibitors of ghrelin O-acyltransferase as potential therapeutic agents for obesity and diabetes
MX343499B (es) * 2010-03-15 2016-11-08 Ipsen Pharma Sas Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento.
RU2475757C1 (ru) * 2012-02-02 2013-02-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера" Министерства здравоохранения и социального развития Российской Федерации Способ прогнозирования тяжести течения послеоперационного периода у больных калькулезным холециститом
JP2015510505A (ja) * 2012-02-03 2015-04-09 ジーランド ファーマ アクティーゼルスカブ グレリン類似体
WO2014156339A1 (ja) * 2013-03-25 2014-10-02 ゼリア新薬工業株式会社 食後期の胃運動亢進剤
CA2978216A1 (en) 2014-03-04 2015-09-11 Motus Therapeutics, Inc. Process for the liquid phase synthesis of h-inp-(d)bal-(d)trp-phe-apc-nh2, and pharmaceutically acceptable salts thereof
CN113072617B (zh) * 2021-03-30 2023-08-08 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用
CN114805487B (zh) * 2022-06-07 2024-03-12 成都诺和晟泰生物科技有限公司 一种多肽化合物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1993A (en) 1841-02-23 Elbridge G Matthews Manufacture of plows
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4962115A (en) 1981-10-01 1990-10-09 Janssen Pharmaceutica N.V. Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives
US5362756A (en) 1989-02-20 1994-11-08 Riviere Pierre J M Use of fedotozine in the treatment of functional states of intestinal obstructions
US5264565A (en) 1991-01-22 1993-11-23 Affymax Technologies, N.V. Nucleic acid encoding the D2 /Ml chimeric receptor
DK0678018T3 (da) 1993-01-06 2003-04-28 Kinerton Ltd Ion molekylærkonjugater af bionedbrydelige polyestere og bioaktive polypeptider
WO1997005252A2 (en) 1995-07-26 1997-02-13 Nps Pharmaceuticals, Inc. Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
EP0900796B1 (en) 1996-04-25 2004-12-15 Fujisawa Pharmaceutical Co., Ltd. Preventives and remedies for ischemic intestinal lesion and ileus
US5929035A (en) 1998-04-14 1999-07-27 Regents Of The University Of Michigan Methods of treating intestinal disorders
EP1197496B8 (en) 1999-07-23 2007-10-03 Kenji Kangawa Novel peptides
DE60140285D1 (de) 2000-05-31 2009-12-10 Pfizer Prod Inc Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts
WO2002008250A2 (en) 2000-07-24 2002-01-31 Ardana Bioscience Limited Ghrelin antagonists
ES2383796T3 (es) 2001-12-18 2012-06-26 Alizé Pharma SAS Composiciones farmacéuticas que comprenden grelina no acilada para su utilización en el tratamiento de la resistencia a la insulina
US7589058B2 (en) 2002-07-23 2009-09-15 Ipsen Pharma, S.A.S. Ghrelin analogs
TWI331922B (en) 2002-08-09 2010-10-21 Ipsen Pharma Sas Growth hormone releasing peptides
CA2514507C (en) 2003-01-28 2012-03-20 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US6911430B2 (en) 2003-10-01 2005-06-28 Vipogen, Llc Compositions and methods for treating ileus
CA2544602A1 (en) 2003-11-04 2005-05-26 Elixir Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
PT1789067E (pt) * 2004-08-12 2012-08-06 Helsinn Healthcare Sa Utilização de hormona do crescimento secretagogo para a estimulação da motilidade do sistema gastrointestinal
JP2008510706A (ja) * 2004-08-18 2008-04-10 エリクシアー ファーマシューティカルズ， インコーポレイテッド 成長ホルモン分泌促進物質
ES2410132T3 (es) 2005-07-22 2013-07-01 Ipsen Pharma Secretagogos de la hormona del crecimiento.
CN101282738B (zh) 2005-09-28 2015-09-16 益普生制药股份有限公司 生长素释放肽类似物
PL1937262T3 (pl) * 2005-09-29 2019-10-31 Ipsen Pharma Kompozycja do stosowania w leczeniu zaburzeń motoryki przewodu pokarmowego
US20100227806A1 (en) 2006-03-10 2010-09-09 Tulipano Giovanni Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
AU2007300526B2 (en) 2006-09-27 2011-07-21 Ipsen Pharma S.A.S. Analogs of ghrelin substituted at the N-terminal
TW200916113A (en) 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
MX343499B (es) 2010-03-15 2016-11-08 Ipsen Pharma Sas Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento.
AU2012356321B2 (en) 2011-12-23 2015-09-17 Ipsen Manufacturing Ireland Limited Process for the synthesis of therapeutic peptides

Also Published As

Publication number Publication date
HUE044391T2 (hu) 2019-10-28
EP1937262A2 (en) 2008-07-02
DK1937262T3 (da) 2019-07-15
WO2007041278B1 (en) 2007-12-06
CN105381453A (zh) 2016-03-09
US20110166069A1 (en) 2011-07-07
WO2007041278A3 (en) 2007-10-04
RU2011103062A (ru) 2012-08-10
US20190248861A1 (en) 2019-08-15
CA2625447C (en) 2015-06-09
CN101287464A (zh) 2008-10-15
RU2008116837A (ru) 2009-11-10
US20170037104A1 (en) 2017-02-09
WO2007041278A2 (en) 2007-04-12
JP5230430B2 (ja) 2013-07-10
PL1937262T3 (pl) 2019-10-31
JP5960563B2 (ja) 2016-08-02
EP3586846A1 (en) 2020-01-01
EP1937262B1 (en) 2019-05-08
ES2740108T3 (es) 2020-02-05
CN105381453B (zh) 2018-11-13
JP2009510098A (ja) 2009-03-12
CN105381453B9 (zh) 2019-01-11
EP1937262A4 (en) 2014-09-24
US8981054B2 (en) 2015-03-17
RU2566708C2 (ru) 2015-10-27
SI1937262T1 (sl) 2019-09-30
CY1122134T1 (el) 2020-11-25
CA2625447A1 (en) 2007-04-12
CN103251933A (zh) 2013-08-21
US20090304724A1 (en) 2009-12-10
US9499599B2 (en) 2016-11-22
US20200347110A1 (en) 2020-11-05
US7932231B2 (en) 2011-04-26
RU2420305C2 (ru) 2011-06-10
JP2013035856A (ja) 2013-02-21
US20150218245A1 (en) 2015-08-06
JP2017095494A (ja) 2017-06-01
JP2015038116A (ja) 2015-02-26
JP6419864B2 (ja) 2018-11-07

Similar Documents

Publication Publication Date Title
PL1937262T3 (pl) Kompozycja do stosowania w leczeniu zaburzeń motoryki przewodu pokarmowego
EP1841558A4 (en) METHOD AND COMPOSITION FOR ELECTROCHEMICAL MECHANICAL POLISHING
IL190106A0 (en) Improvements in sealing apparatus
EP1930012A4 (en) COMPOSITION CONTAINING A CELLO-OLIGOSACCHARIDE
GB0619096D0 (en) Polishing composition and polishing method
GB2429713B (en) Polishing composition
EP1865042A4 (en) ANTI-FREEZE COMPOSITION
GB0508250D0 (en) Composition
GB0506044D0 (en) Composition
EP1847249A4 (en) hair dye
IL176829A0 (en) Composition for treating pathology associated with msrv/herv-w
GB0507167D0 (en) Composition
SG131098A1 (en) Polishing composition and polishing method
EP1947129A4 (en) PHOTORADIC AND PHOTOCYSTIC CURING COMPOSITION
TWI346671B (en) Chemical composition and process
EP1864573A4 (en) AGRICULTURAL CHEMICAL COMPOSITION
GB0513641D0 (en) Anti-egeing composition
GB0607488D0 (en) Composition and process
GB0605004D0 (en) Composition and process
GB0510286D0 (en) Composition
GB0607493D0 (en) Composition and process
GB0614798D0 (en) Composition and process
GB0607486D0 (en) Composition and process
GB0607491D0 (en) Composition and process
GB0515017D0 (en) Composition